Tag: Rybrevant for NSCLC

Home / Rybrevant for NSCLC

Categories

Amivantamab-vmjw is approved by the USFDA for EGFR exon 20 insertion-mutated non-small cell lung cancer indications

The Food and Drug Administration approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in combination with carboplatin and pemetrexed on March 1, 2024. Patients with epidermal growth factor re...
rybrevant-for-nsclc

Scan the code